Vanda pharmaceuticals inc. (VNDA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Net Income (Loss) Attributable to Parent

115,553

25,208

-15,567

-18,010

-39,865

20,186

-21,055

-27,664

-9,802

7,192

-35,859

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation of property and equipment

1,400

1,400

1,200

900

582

530

432

633

469

336

442

Stock-based compensation

13,458

11,666

10,465

8,543

7,961

5,878

5,404

4,094

5,501

4,982

11,230

Loss on disposal of assets

-

-

-

-

-

-

-

-

-

23

-

Amortization of discounts and premiums on marketable securities

3,099

2,221

426

-62

-677

-174

-155

-560

-900

-212

-138

Intangible asset amortization

1,505

1,527

1,750

10,933

12,972

2,254

1,495

1,495

1,495

1,495

983

Deferred income taxes

-87,767

0

0

-

-

-

-

-

1,821

-1,821

-

Gain on arbitration settlement

-

-

-

-

-

77,616

-

-

-

-

-

Other non-cash adjustments, net

-1,785

-167

-587

-542

-483

-239

-104

-

-

-

-

Excess tax benefits from exercise of stock options

-

-

-

-

-

-

-

-

-

2,892

-

Landlord contributions for tenant improvements

-

-

-

-

-

-

-

1,826

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-2,342

11,207

-2,525

4,298

12,677

1,623

863

-450

1,107

-2,653

3,164

Prepaid expenses and other assets

2,764

4,258

-3,652

6,159

2,558

318

-1,264

884

1,240

-250

805

Accounts payable

-

-

-

-

-

-

-

-709

348

-1,776

1,911

Inventory

722

-70

1,060

-200

-387

2,210

-

-

-

-2,399

2,399

Accounts payable and other liabilities

3,508

-618

5,953

575

9,432

1,029

261

-

-

-

-

Product revenue allowances

761

8,223

-11,096

-1,426

35,055

495

-

-

-

-

-

Other liabilities

-

-

-

-

-

-

-

265

424

-17

5

Accrued liabilities

-

-

-

-

-

-

-

1,806

1,836

-997

-577

Accrued income taxes

-

-

-

-

-

-

-

-

-2,266

3,898

-

Deferred licensing revenues

-

-

-

-

-

-30,572

-26,789

-26,789

-26,789

-26,789

197,431

Net cash provided by operating activities

45,947

29,986

-1,983

-8,103

12,449

-81,554

-39,592

-44,917

-28,410

-10,898

169,336

Cash flows from investing activities
Acquisition of intangible asset

0

25,000

0

0

-

8,000

-

-

-

-

12,000

Purchases of property and equipment

1,019

368

1,664

1,407

2,527

769

176

2,017

275

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

66

-

Purchases of marketable securities

394,517

282,395

148,135

165,405

193,111

93,343

65,598

60,866

160,213

202,438

11,366

Proceeds from sale of marketable securities

-

-

-

-

999

8,948

-

2,497

8,667

-

127

Maturities of marketable securities

327,227

198,103

139,568

156,787

168,041

80,882

31,499

106,140

226,170

46,750

18,500

Change in restricted cash

-

-

-

-

-

-245

-

-

600

-

-

Net cash used in investing activities

-68,309

-109,660

-10,231

-10,025

-26,598

-12,037

-34,275

45,754

73,749

-155,622

-4,739

Cash flows from financing activities
Proceeds from Issuance of Common Stock

0

100,870

0

0

-

62,313

48,505

-

-

-

-

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

2,892

-

Proceeds from Stock Options Exercised

6,300

6,300

5,300

7,751

4,374

2,851

1,550

12

25

892

1,619

Tax obligations paid in connection with settlement of restricted stock units

-

-

-

-

283

436

196

-

-

-

-

Net cash provided by financing activities

6,264

107,126

5,251

7,751

4,091

89,728

49,859

12

25

3,784

1,619

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-1

-38

42

5

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

-16,099

27,414

-6,921

-10,372

-10,058

-3,863

-24,008

849

45,364

-162,736

166,216

Non-cash investing and financing activities
Purchases of property and equipment accrued in current liabilities

-

-

-

-

-

-

106

-

221

-

-